Advertisement

Obesity Surgery

, Volume 18, Issue 12, pp 1532–1538 | Cite as

Ursodeoxycholic Acid in the Prevention of Gallstone Formation after Bariatric Surgery: A Meta-analysis

  • Manley C. UyEmail author
  • Marilyn C. Talingdan-Te
  • Wendell Z. Espinosa
  • Ma. Lourdes O. Daez
  • Janus P. Ong
Other

Abstract

Background

Rapid weight loss increases risk for gallstone formation. Prophylactic cholecystectomy is difficult. Several small trials have shown that ursodeoxycholic acid (UDCA) may prevent gallstone formation after bariatric surgery. The aim of this study is to assess the efficacy and safety of UDCA in the prevention of gallstone formation after bariatric surgery.

Methods

Electronic databases, including the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Australasian Medical Index, LILACS, and HERDIN, were searched. Reference lists of trials selected by the above electronic searching were also searched. Authors of the retrieved trials and pharmaceutical companies were also contacted for other trials, published and unpublished. A meta-analysis of all randomized, double-blind, placebo-controlled prospective trials comparing UDCA and placebo was performed.

Results

Five RCTs including 521 patients were assessed. Random effects meta-analysis showed a significant reduction of gallstone formation (RR 0.43, 95% confidence interval 0.22–0.83), with 8.8% of those taking UDCA developing gallstones compared to 27.7% for placebo. Although this meta-analysis is heterogeneous with I 2 of 61.9%, the directions of the effect are all consistently in favor of UDCA (p = 0.01). A meta-analysis on the adverse effects could not be performed because the studies did not report them in a way to make the analysis possible.

Conclusions

UDCA can prevent gallstone formation after bariatric surgery.

Keyword

Ursodeoxycholic acid Gallstone Bariatric surgery Meta-analysis 

References

  1. 1.
    Wudel LJ, Wright JK, Debelak JP, et al. Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. J Surg Res. 2002;102(1):50–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Worobetz LJ, Inglis FG, Shaffer EA. The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss. Am J Gastroenterol. 1993;88(10):1705–10.PubMedGoogle Scholar
  3. 3.
    Miller K, Hell E, Lang B, et al. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg. 2003;238(5):697–702.PubMedCrossRefGoogle Scholar
  4. 4.
    Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg. 1995;169:91–7.PubMedCrossRefGoogle Scholar
  5. 5.
    The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions 4.2.6. updated September 2006.Google Scholar
  6. 6.
    Williams CN, Gowan R, Perey BJ. A double-blind placebo-controlled trial of ursodeoxycholic acid in the prevention of gallstones during weight loss after vertical banded gastroplasty. Obes Surg. 1993;3:257–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Taylor J, Leitman M, Horowitz M. Is routine cholecystectomy necessary at the time of roux-en-y gastric bypass? Obes Surg. 2006;16:759–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Fuller W, Rasmussen JJ, Ghosh J, Ali MR. Is routine cholecystectomy indicated for asymptomatic cholelithiasis in patients undergoing gastric bypass? Obes Surg. 2007;17:747–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Scott DJ, Villegas L, Sims TL, Hamilton EC, Provost DA, Jones DB. Intraoperative ultrasound and prophylactic ursodiol for gallstone prevention following laparoscopic gastric bypass. Surg Endosc. 2003;17:1796–802.PubMedCrossRefGoogle Scholar
  10. 10.
    Shiffman ML, Kaplan GD, Brinkman-Kaplan V, et al. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Int Med. 1995;122(12):899–905.PubMedGoogle Scholar
  11. 11.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc. 2004;292(14):1724–37.CrossRefGoogle Scholar
  12. 12.
    Broomfield PH, Chopra R, Sheinbaum RC, et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med. 1998;319(24):1567–72.Google Scholar
  13. 13.
    Lafferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.CrossRefGoogle Scholar
  14. 14.
    Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. Philadelphia: Saunders Elsevier; 2006.Google Scholar
  15. 15.
    Tan-Tin Hay LM, Oliveros E, Esguerra E, et al. A review of the metabolic profile of patients undergoing bariatric surgery in St. Luke’s Medical Center (2002–2004). Philipp J Int Med. 2005;43:323–30.Google Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Manley C. Uy
    • 1
    Email author
  • Marilyn C. Talingdan-Te
    • 1
  • Wendell Z. Espinosa
    • 1
  • Ma. Lourdes O. Daez
    • 1
  • Janus P. Ong
    • 1
  1. 1.Section of Gastroenterology, Department of Medicine, Philippine General HospitalUniversity of the PhilippinesManilaPhilippines

Personalised recommendations